Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state

被引:46
作者
Härkönen, P
Törn, S
Kurkela, R
Porvari, K
Pulkka, A
Lindfors, A
Isomaa, V
Vihko, P
机构
[1] Oulu Univ, Res Ctr Mol Endocrinol, FIN-90014 Oulu, Finland
[2] Bioctr Oulu, FIN-90014 Oulu, Finland
关键词
D O I
10.1210/jc.2002-020236
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The progression of prostate cancer during androgen deprivation therapy is a serious clinical problem. Little is known, however, about the mechanisms behind the transition of the disease to an androgen-independent stage. In the present report, we provide evidence of substantial changes in both estrogen and androgen metabolism during the transition of cultured prostate cancer LNCaP (lymph node carcinoma of the prostate) cells. The results of enzyme activity measurements performed using HPLC suggest that, related to the transition, there exists a remarkable decrease in the oxidative 17beta-hydroxysteroid dehydrogenase (17HSD) activity, whereas the reductive 17HSD activity seems to increase. Relative quantitative RT-PCR revealed that the decrease in oxidative activity largely coincided with the remarkable decrease in the expression of the HSD17B2 gene. Furthermore, the present data suggest that the observed increasing activity of 17HSD type 7 could lead to the increased intracellular production of 17beta-estradiol during disease progression. This was supported by the cDNA microarray screening results, which showed a considerable overexpression of several estrogen up-regulated genes in the LNCaP cell line variant that represents progressive prostate cancer. Because 17HSDs critically contribute to the control of bioavailability of active sex steroid hormones locally in the prostate, the observed variation in intraprostatic 17HSD activity might be predicted to be crucially involved in the regulation of growth and function of the organ.
引用
收藏
页码:705 / 712
页数:8
相关论文
共 46 条
[1]  
Bosland M C, 2000, J Natl Cancer Inst Monogr, P39
[2]  
Coffey D.S., 1988, P1081
[3]   A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].
CRAWFORD, ED ;
EISENBERGER, MA ;
MCLEOD, DG ;
SPAULDING, JT ;
BENSON, R ;
DORR, FA ;
BLUMENSTEIN, BA ;
DAVIS, MA ;
GOODMAN, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :419-424
[4]  
DUFFY MJ, 1988, CANCER RES, V48, P1348
[5]   Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase [J].
Dufort, I ;
Rheault, P ;
Huang, XF ;
Soucy, P ;
Luu-The, V .
ENDOCRINOLOGY, 1999, 140 (02) :568-574
[6]   Three independently deleted regions at chromosome arm 16q in human prostate cancer:: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient [J].
Elo, JP ;
Härkönen, P ;
Kyllönen, AP ;
Lukkarinen, O ;
Vihko, P .
BRITISH JOURNAL OF CANCER, 1999, 79 (01) :156-160
[7]  
Elo JP, 1997, CANCER RES, V57, P3356
[8]  
Elo JP, 1996, INT J CANCER, V66, P37, DOI 10.1002/(SICI)1097-0215(19960328)66:1<37::AID-IJC7>3.3.CO
[9]  
2-Q
[10]   MALE PSEUDOHERMAPHRODITISM CAUSED BY MUTATIONS OF TESTICULAR 17-BETA-HYDROXYSTEROID DEHYDROGENASE-3 [J].
GEISSLER, WM ;
DAVIS, DL ;
WU, L ;
BRADSHAW, KD ;
PATEL, S ;
MENDONCA, BB ;
ELLISTON, KO ;
WILSON, JD ;
RUSSELL, DW ;
ANDERSSON, S .
NATURE GENETICS, 1994, 7 (01) :34-39